# US 2013/0261053 A1 · Glial cell line-derived neurotrophic factor (gdnf) compositions and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0261053 A1
- Document ID: US20130261053A1
- Status: Published application
- Kind: A1
- Application number: 13/855,533
- Filed: 2013-04-02
- Published: 2013-10-03
- Earliest claimed: 2012-04-02
- Assignees: Services; The United States of America, as represented by the Secretary, Department of Health and Human
- Inventors: Qing-Rong Liu
- Web page: https://patentgrep.com/patent/US20130261053A1

## CPC

- C07K 14/47: from mammals
- C07K 14/475: Growth factors; Growth regulators
- C07K 16/22: against growth factors {; against growth regulators}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Described herein is the identification of primate-specific glial cell line-derived neurotrophic factor opposite strand (GDNFOS) transcripts and encoded peptides. In particular embodiments, provided herein are three GDNFOS antisense transcripts, referred to as GDNFOS-1, GDNFOS-2 and GDNFOS-3. The GDNFOS-3 transcript encodes an ORF of 105 amino acids. Compositions comprising the GDNFOS transcripts and peptides are also provided by the present disclosure. Further provided are methods of treating a neurodegenerative or peripheral organ disease in a subject by administering a therapeutically effective amount of the disclosed GDNFOS nucleic acid molecules, peptides or compositions.

## Claims

### Claim 1

An isolated glial cell line-derived neurotrophic factor opposite strand (GDNFOS) nucleic acid molecule comprising a nucleotide sequence at least 90% identical to SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3.

### Claim 2 (depends on 1)

The GDNFOS nucleic acid molecule of claim 1, wherein the nucleotide sequence of the nucleic acid molecule is at least 95% identical to SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3.

### Claim 3 (depends on 1)

The GDNFOS nucleic acid molecule of claim 1, wherein the nucleotide sequence of the nucleic acid molecule comprises or consists of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3.

### Claim 4 (depends on 1)

An isolated GDNFOS peptide encoded by the nucleic acid molecule of claim 1.

### Claim 5 (depends on 1)

A vector comprising the nucleic acid molecule of claim 1.

### Claim 6 (depends on 5)

An isolated cell comprising the vector of claim 5.

### Claim 7 (depends on 1)

A composition comprising a pharmaceutically acceptable carrier and the nucleic acid molecule of claim 1.

### Claim 8 (depends on 7)

The composition of claim 7, further comprising a nucleic acid molecule encoding a glial cell line-derived neurotrophic factor (GDNF) protein, or a biologically active fragment or variant thereof.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the GDNF protein comprises human GDNF of SEQ ID NO: 45 or the biologically active fragment of GDNF comprises the DNSP-11 peptide of SEQ ID NO: 44.

### Claim 10

An isolated GDNFOS peptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 4, SEQ ID NO: 42, SEQ ID NO: 43 or residues 29-105 of SEQ ID NO: 4.

### Claim 11 (depends on 10)

The GDNFOS peptide of claim 10, comprising an amino acid sequence at least 95% identical to SEQ ID NO: 4, SEQ ID NO: 42, SEQ ID NO: 43 or residues 29-105 of SEQ ID NO: 4.

### Claim 12 (depends on 10)

The GDNFOS peptide of claim 10, wherein the amino acid sequence of the peptide comprises or consists of SEQ ID NO: 4, SEQ ID NO: 42, SEQ ID NO: 43 or residues 29-105 of SEQ ID NO: 4.

### Claim 13 (depends on 10)

A composition comprising the GDNFOS peptide of claim 10 and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 13)

The composition of claim 13, further comprising a GDNF protein, or a biologically active fragment or variant thereof.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the GDNF protein comprises human GDNF of SEQ ID NO: 45 or the biologically active fragment of GDNF comprises the DNSP-11 peptide of SEQ ID NO: 44.

### Claim 16 (depends on 1)

A method of treating a neurodegenerative disease or diabetes mellitus in a subject, comprising selecting a subject with a neurodegenerative disease or diabetes, and administering to the subject a therapeutically effective amount of the isolated GDNFOS nucleic acid molecule of claim 1, thereby treating the neurodegenerative disease or diabetes mellitus.

### Claim 17 (depends on 16)

The method of claim 16, wherein the neurodegenerative disease is selected from Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis and amyotrophic lateral sclerosis.

### Claim 18 (depends on 13)

A method of treating a neurodegenerative disease or diabetes mellitus in a subject, comprising selecting a subject with a neurodegenerative disease or diabetes, and administering to the subject a therapeutically effective amount of the isolated GDNFOS peptide of claim 13, thereby treating the neurodegenerative disease or diabetes mellitus.

### Claim 19 (depends on 18)

The method of claim 18, wherein the neurodegenerative disease is selected from Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis and amyotrophic lateral sclerosis.

### Claim 20

An antibody or antigen-binding fragment thereof that specifically binds an epitope of a GDNFOS protein comprising the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 42 or SEQ ID NO: 43.

### Claim 21 (depends on 20)

The antibody of claim 20, wherein the antibody is a polyclonal antibody.

### Claim 22 (depends on 20)

The antibody of claim 20, wherein the antibody is a monoclonal antibody.
